Next Article in Journal
New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment
Previous Article in Journal
Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
Biomedicines 2018, 6(3), 86; https://doi.org/10.3390/biomedicines6030086

Emerging Medical Treatments for Meningioma in the Molecular Era

1
Brain Tumor Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2
Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
3
Department of Neurosurgery, McMaster University, Hamilton, ON 8L8 2X2, Canada
4
Department of Neurosurgery and Neuroscience, Maastricht University Medical Center, 6229 HY Maastricht, The Netherlands
*
Author to whom correspondence should be addressed.
Received: 27 July 2018 / Accepted: 31 July 2018 / Published: 6 August 2018
Full-Text   |   PDF [294 KB, uploaded 6 August 2018]   |  

Abstract

Meningiomas are the most common type of primary central nervous system tumors. Approximately, 80% of meningiomas are classified by the World Health Organization (WHO) as grade I, and 20% of these tumors are grade II and III, considered high-grade meningiomas (HGMs). Clinical control of HGMs, as well as meningiomas that relapse after surgery, and radiation therapy is difficult, and novel therapeutic approaches are necessary. However, traditional chemotherapies, interferons, hormonal therapies, and other targeted therapies have so far failed to provide clinical benefit. During the last several years, next generation sequencing has dissected the genetic heterogeneity of meningioma and enriched our knowledge about distinct oncogenic pathways driving different subtypes of meningiomas, opening up a door to new personalized targeted therapies. Molecular classification of meningioma allows a new design of clinical trials that assign patients to corresponding targeted agents based on the tumor genetic subtypes. In this review, we will shed light on emerging medical treatments of meningiomas with a particular focus on the new targets identified with genomic sequencing that have led to clinical trials testing novel compounds. Moreover, we present recent development of patient-derived preclinical models that provide platforms for assessing targeted therapies as well as strategies with novel mechanism of action such as oncolytic viruses. View Full-Text
Keywords: World Health Organization (WHO); Grade I, II, and III Meningiomas; High Grade Meningiomas (HGMs); tumor heterogeneity; genetic subtypes; overall survival (OS); progression free survival (PFS); targeted therapy; clinical trials; oncolytic virus (OV) World Health Organization (WHO); Grade I, II, and III Meningiomas; High Grade Meningiomas (HGMs); tumor heterogeneity; genetic subtypes; overall survival (OS); progression free survival (PFS); targeted therapy; clinical trials; oncolytic virus (OV)
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Nigim, F.; Wakimoto, H.; Kasper, E.M.; Ackermans, L.; Temel, Y. Emerging Medical Treatments for Meningioma in the Molecular Era. Biomedicines 2018, 6, 86.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top